Treatment with PUGNAc (OGA inhibitors) and glucosamine to increase the level of O-GlcNAcylation can significantly reduce the expression of ERα in ER positive breast cancer cells and protect the cells from tamoxifen-induced death [105]. This evidence concerns the gene ESR1 and breast carcinoma.